Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000484122 | SCV000556328 | likely benign | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000484122 | SCV000572679 | uncertain significance | not provided | 2017-01-09 | criteria provided, single submitter | clinical testing | This variant is denoted POLE c.2016G>A at the DNA level. This variant is silent at the coding level, preserving an Arginine at codon 672. It is not predicted to cause abnormal splicing. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. POLE c.2016G>A was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. The nucleotide which is altered, a guanine (G) at base 2016, is conserved in mammals. Based on currently available evidence, it is unclear whether POLE c.2016G>A is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. |
Ambry Genetics | RCV002418448 | SCV002724343 | likely benign | Hereditary cancer-predisposing syndrome | 2018-08-31 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |